Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

American Journal of Hematology

Volumn 86, Issue 1, 2011, Pages 102-103

  Sekeres, Mikkael A ^a   O'Keefe, Christine ^a   List, Alan F ^b   Paulic, Katarina ^a   Afable, Manuel ^a   Englehaupt, Ricki ^a   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; LENALIDOMIDE;

ADD ON THERAPY; ADULT; AGED; CASE REPORT; CHROMOSOME DELETION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPING; LETTER; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; AZACITIDINE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THALIDOMIDE;

EID: 78650405873     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21891     Document Type: Letter

References (16)

1. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004: 297-317.
2. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432.
3. Vardiman J, Thiele J, Arber D, et al. The 2008 Revisions of the WHO classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
4. Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology 2009; 2009: 645-655.
5. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100: 1542-1551.
6. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
7. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
8. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
9. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci 2009; 106: 12974-12979.
10. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335-339.
11. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-1325.
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
13. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010; 28: 2253-2258.
14. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425. Epub 2006 Apr 2011.
15. Koch R. Über den augenblicklichen Stand der bakteriologischen Choleradiagnose. Zeitschrift für Hygiene und Infectionskrankheiten 1893; 14: 319-333.
16. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.